Basic Information
VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG
TABLET, FILM COATED
Regulatory Information
SIN15705P
May 31, 2019
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XJ05AP56
Company Information
GILEAD SCIENCES SINGAPORE PTE. LTD.
GILEAD SCIENCES SINGAPORE PTE. LTD.
Active Ingredients
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Concomitant use with medicinal products that are strong P-glycoprotein (P-gp) and/or strong cytochrome P450 (CYP) inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin and St. John’s wort) (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Concomitant use with rosuvastatin or dabigatran etexilate (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Concomitant use with ethinylestradiol-containing medicinal products such as combined oral contraceptives or contraceptive vaginal rings (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).